Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT04084561 Completed - Lung Cancer Clinical Trials

Risk Communication in African American Smokers

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

The study aims to understand the effects of learning about one's genetic risk for lung cancer that is specific to their ancestry. Participants will be given hypothetical personalized genetic risk results and ask to think about how they might respond to such information if they actually received such results.

NCT ID: NCT04079400 Completed - Lung Cancer Clinical Trials

Microbiome in Pulmonary Tuberculosis, Non-tuberculous Mycobacterial Pulmonary Diseases, Lung Cancer and Hemoptysis

Start date: December 1, 2016
Phase:
Study type: Observational [Patient Registry]

Microbiome in lower respiratory diseases is not sufficiently known yet. The objective of this study is to investigate microbiome in patients who present with hemoptysis, and those with pulmonary tuberculosis, non-tuberculous mycobacterial pulmonary disease (NTM-PD), and lung cancer, analyzing respiratory specimen acquired by bronchoscopic approach.

NCT ID: NCT04074460 Completed - Cancer, Breast Clinical Trials

Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study

VAPOR-C
Start date: August 27, 2017
Phase: Phase 4
Study type: Interventional

A multicentre, prospective randomized, active-controlled feasibility trial of volatile-based anaesthesia vs. propofol-based total intravenous anaesthesia to investigate the impact of anaesthesia on long-term (i.e. 5-years) patient cancer outcomes in patients undergoing elective major cancer surgery.

NCT ID: NCT04070586 Completed - Cancer, Lung Clinical Trials

Adaptive CT Acquisition for Personalised Thoracic Imaging

ADAPT
Start date: August 21, 2019
Phase:
Study type: Observational

In this trial, Respiratory Motion Guided (RMG) 4DCBCT will be implemented for the first time on lung cancer patients. RMG-4DCBCT adapts the image acquisition as the patient's breathing changes (i.e. if the patient breathes faster, imaging data is acquired faster). By adapting the acquisition to the dynamic patient, personalised images of a patients lungs are able to be acquired for radiotherapy treatments.

NCT ID: NCT04069663 Completed - Clinical trials for Non Small Cell Lung Cancer

Efficacy of Re-challenge With Immune-Checkpoints Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients: a Retrospective Observational Study

RE-CHALLENGE
Start date: January 22, 2019
Phase:
Study type: Observational

This is a multicentre, retrospective, national observational study aiming to describe clinical outcomes of advanced NSCLC patients that performed an ICP re-challenge during their history of disease. The objective of this study is to evaluate the ICP re-challenge efficacy.

NCT ID: NCT04069494 Completed - Clinical trials for Advanced Lung Cancer

Descriptors and Predictors of Burden and Information Needs

Start date: October 1, 2019
Phase:
Study type: Observational [Patient Registry]

the purpose of this study is to investigate over time patients' symptom burden, caregiving burden, and patients and caregivers' need for information on patient symptom self-management at home during palliative radiotherapy(RT) for lung cancer. Repeatedly assessing burden and information needs on symptom self-management at home can help healthcare professionals to design a bespoke service and plan of care for both patients and family caregivers. In addition, I will explore psycho-social and clinical predictors of burden and information needs in patients and caregivers. These predictors can help health professionals to identify patients and caregivers at risk for distress during palliative radiotherapy for lung cancer.

NCT ID: NCT04061356 Completed - Lung Cancer Clinical Trials

Assessment of Exhaled Breath Condensate Hydrogen Peroxide (EBC H2O2) as Measured Using a New Device (Inflammacheck™) in Patients With Interstitial Lung Disease, Lung Cancer and Healthy Volunteers.

EXHALE 1B
Start date: October 30, 2018
Phase:
Study type: Observational

A cross-sectional study of EBC H2O2 levels, as measured by a novel device, 'Inflammacheck™', and other markers of disease severity in patients with ILD and Lung Cancer.

NCT ID: NCT04059887 Completed - Clinical trials for Lung Neoplasm Malignant

Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]

BUDDY
Start date: December 18, 2019
Phase: Phase 4
Study type: Interventional

This is single arm, prospective, multi-center, cohort study to evaluate blood TMB for improved efficacy of atezolizumab in locally advanced or metastatic NSCLC at the study enrollment who failed one or more prior lines of chemotherapy including at least 1 platinum-based.

NCT ID: NCT04057196 Completed - Clinical trials for Lung Cancer Stage IV

Self-System Therapy for Older Adults With Lung Cancer

Start date: April 2, 2020
Phase: N/A
Study type: Interventional

The purpose of this study to use Self-system therapy (SST), to treat depression and lung-cancer-related distress in older adults (65 years and older).

NCT ID: NCT04055792 Completed - Clinical trials for Extensive Disease Small Cell Lung Cancer

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

Start date: September 11, 2019
Phase: Phase 2
Study type: Interventional

Small cell lung cancer (SCLC) accounts for 10-15% of lung cancer. More than 70% of SCLC patients are diagnosed with advanced stage (ED-SCLC) at diagnosis. ED-SCLC is highly chemo-sensitive, the first-line treatment is platinum-containing double-drug chemotherapy. Although ED-SCLC is highly sensitive to chemotherapy and the objective response rate (ORR) of first-line chemotherapy is as high as 60-80%, the progression-free survival (PFS) is very short, and there is a lack of effective second-line treatment. The median overall survival (OS) of patients is only 10 months, and the 2-year survival rate is about 6%.